Additionally, it remains uncertain whether CD33’s association with neurodegenerative diseases extends beyond Alzheimer’s disease, which cognitive domains are most affected and the underlying mechanisms. This evidence concerns the gene CD33 and early-onset autosomal dominant Alzheimer disease.